Issue of Shares Pursuant to Incentive Scheme

Syncona Limited

19 July 2024

 

Syncona Limited

Issue of shares pursuant to incentive scheme and PDMR dealings

19 July 2024

Syncona Ltd (the "Company"), a leading life science investor focused on creating, building and scaling global leaders in life science, today announces that a total of 407,966 new ordinary shares (representing approximately 0.06% of the Company's existing issued ordinary shares, excluding shares held in treasury) will be issued in satisfaction of realisations under the Company's long term incentive scheme.  The new ordinary shares, when issued, will rank pari passu with the existing issued ordinary shares of the Company. In accordance with the rules of the incentive scheme, the number of ordinary shares to be issued has been calculated using the closing mid-market price on 17 July, 2024, £1.25.

In accordance with the rules of the incentive scheme, ordinary shares delivered on realisation may not be sold or transferred by the recipient for a period of one year following the realisation date.

The issue of shares includes the following shares to be issued to senior members of the Syncona Investment Management Limited (SIML) leadership team:

Name	SIML Title	No. of shares to be issued
Chris Hollowood	Chief Executive Officer	134,082

Application will be made to the Financial Conduct Authority for the shares to be admitted to the Official List, and to the London Stock Exchange for the shares to be admitted to trading and it is expected that dealings will commence in the new ordinary shares on 24 July 2024.

Notification of transactions by Persons Discharging Managerial Responsibilities ("PDMRs") are set out below.

[ENDS]

Enquiries

Syncona Ltd

Natalie Garland-Collins / Fergus Witt

Tel: [phone]

FTI Consulting

Ben Atwell / Tim Stamper

Tel: [phone] 

About Syncona

Syncona's purpose is to invest to extend and enhance human life. We do this by creating, building and scaling companies to deliver transformational treatments to patients in areas of high unmet need.

We aim to build and maintain a diversified portfolio of 20-25 globally leading life science businesses, across development stage, modality and therapeutic area, for the benefit of all our stakeholders. We focus on developing treatments that deliver patient impact by working in close partnership with world-class academic founders and experienced management teams. Our balance sheet underpins our strategy, enabling us to take a long-term view as we look to improve the lives of patients with no or poor treatment options, build sustainable life science companies and deliver strong risk-adjusted returns to shareholders.

Syncona Limited seeks to achieve returns over the long term. Investors should seek to ensure they understand the risks and opportunities of an investment in Syncona Limited, including the information in our published documentation, before investing.

Copies of this press release and other corporate information can be found on the company website at: www.synconaltd.com

1.	Details of PDMR / person closely associated with them ("PCA")
a)	Name	Chris Hollowood
2.	Reason for the notification
a)	Position / status	Chair and Chief Executive Officer, SIML
b)	Initial notification / amendment	Initial Notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Syncona Limited
b)	LEI	213800X8MBI5VQITLW60
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument	Ordinary shares  GG00B8P59C08
b)	Nature of the transaction	Issue of shares pursuant to the Syncona long term incentive scheme
c)	Price(s) and volume(s)	Price(s) £1.25 Volume(s) 134,082
d)	Aggregated information Aggregated volume Price	N/A
e)	Date of the transaction	18 July 2024
)	Place of the transaction	Outside a trading venue
g)	Currency	GBP - British Pound

 

END